Novo Nordisk Plans $4.1 Billion Investment in U.S. Facility Since 2024
Key Facts
Novo Nordisk announced on June 24, 2024, plans to invest $4.1 billion in a second fill-and-finish facility in Clayton, North Carolina, to increase production of current and future injectable treatments for obesity and serious chronic diseases. The announcement dates to that time, not October 2026, as current circulation of the news may suggest. The company said the project aims to expand its production capacity and meet rising global demand for medicines. The announcement did not specify that the facility would produce any particular drugs. The project forms part of the company’s plans to expand manufacturing, while the share price recorded later does not establish a direct link between its movement and this older announcement.
The facility adds 1.4 million square feet of production space, which the company said would double the combined area of its three existing North Carolina facilities at the time of the announcement. This gives the project significant scale within the company’s regional industrial footprint: it is not simply adding lines to an existing site, but involves a second fill-and-finish facility in Clayton. Novo said site preparation and foundation work had already begun on the 56-acre site. That description indicates the project had entered the fieldwork phase when it was announced in 2024. The stated aim remains to increase capacity to produce current and future injectable treatments.
The company estimated that the project would add 1,000 new jobs, alongside about 2,500 employees it had in the region at the time of the announcement. It also expected about 2,000 external contractors to be involved at the peak of construction. It said construction would be completed in stages between 2027 and 2029, putting the facility’s final stages on a timeline spanning several years after the investment announcement. These figures link the project to local expansion in employment and construction, as well as increased industrial capacity. The chief executive at the time said: "It took us a century to reach 40 million patients," adding that continued investment in global production aimed to enable the company to serve millions more people with serious chronic diseases.
The North Carolina investment was part of a broader increase in announced production spending for 2024. Novo Nordisk said it planned to allocate about $6.8 billion to production that year, compared with actual investments of $3.9 billion in 2023. In its 2025 annual report, it said it had spent more than 60 billion Danish kroner, mostly on expanding production capacity to meet demand for current and future products. Sales of obesity-care products reached 82.347 billion Danish kroner in 2025, up 31% at constant exchange rates. The company said the recorded global obesity-drug market doubled in size that year, amid rising competition and a loss of volume share in the GLP-1 obesity and diabetes drug markets.
Product-mix expectations have shifted as the market has expanded. Goldman Sachs raised its estimate for global obesity-drug sales in 2030 by 15% to $114 billion in 2026, and forecast that oral medicines would account for 40% of the market. It also said eligible Medicare beneficiaries could apply for coverage of oral and injectable obesity medicines starting July 1, 2026, with coverage expected to be adopted gradually. In the United States, Wegovy pills are now produced domestically: the active ingredient is made in Clayton, while the tablets are manufactured and packaged in Durham. Novo’s chief executive told Reuters in August 2026 that new treatment options, including pills, would make the market more fragmented, and that competition would not be a winner-takes-all battle.
Company data in its second-quarter 2026 update showed U.S. weekly prescriptions for Wegovy pills topped 265,000 in the week ended July 17, with plans to launch the pills in additional markets over the following quarters. On supply, the company said the U.S. Food and Drug Administration announced in February 2025 that the shortage of semaglutide injections had ended, confirming that supplies met current and projected U.S. demand. Novo Nordisk estimated capital expenditure at about 55 billion Danish kroner in 2026, saying the investments would add capacity and flexibility to its supply chain, including active-ingredient manufacturing, filling and finishing. The company also announced in March 2026 a 432 million euro investment to expand its facility in Athlone, Ireland, supporting manufacturing capacity for current and future GLP-1 treatments outside the United States. Novo Nordisk shares closed at $39.05 on October 23, 2026, according to EL7 data.